| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23N3OS |
| Molecular Weight | 365.492 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1CCN(CCCN2C3=CC(=CC=C3SC4=C2C=CC=C4)C#N)CC1
InChI
InChIKey=LUALIOATIOESLM-UHFFFAOYSA-N
InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
| Molecular Formula | C21H23N3OS |
| Molecular Weight | 365.492 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Periciazine (INN), also known as pericyazine (BAN) or Propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics. Pericyazine is not approved for sale in the United States. It is commonly sold in Canada and Russia under the tradename Neuleptil and in the United Kingdom and Australia under the tradename Neulactil. The primary uses of pericyazine include the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether periciazine is more or less effective than other antipsychotics. Pericyazine is a rather sedating and anticholinergic antipsychotic, and despite being classed with the typical antipsychotics, its risk of extrapyramidal side effects is comparatively low. It has a relatively high risk of causing hyperprolactinemia and a moderate risk of causing weight gain and orthostatic hypotension.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
50 mg/day for two days, thereafter a flexible dosage schedule was followed until therapeutic effect achieved.
Route of Administration:
Oral
One hundred microlitres of [3H]SCH23390 (1 nM, 90 Ci/mmol), competing drug solution (100 mkl of variable concentrations) and 50 mM Tris-HCl buffer (700 gl) containing no NaCl or KCI were placed in glass tubes. The solutions were stirred using a vortex mixer. One hundred microlitres of membrane preparation (2.5 mg wet tissue/tube) were added and the solution was again stirred using a vortex mixer. Solutions were incubated for 30 min at 37 C. Incubations were terminated by rapid filtration under vacuum using Whatman GF/B filters (24 mm diameter). The tubes and filters were rinsed with 6 ml ice-cold saline. The filters were punched out and placed in a 20 ml glass vial with 10 ml scintillation cocktail. After the samples stood six hours, radioactivities were measured using a Beckman LS 7800 liquid scintillation counter. The specific bound was defined as the total amount of [3H]SCH23390 bound (zero unlabelled ligands) minus the nonspecific amount bound (binding in presence of 1mkM SCH23390).
